Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Emory University

Atlanta, Georgia 30322, United StatesEmory University

242running trials
111closed trials

Part of

Emory University

Trial registries list Emory University under 29 sites and names; the figures below count all of them.

466trials across all its sites
316of them running
29registry sites and names
231,755publications (OpenAlex)

Type (ROR): Education
Website: emory.edu
Publishes most on: HIV
Stroke
Alzheimer disease
Obesity
Heart failure
Type 2 diabetes

See all 466 trials at Emory University

Institution data from ROR and OpenAlex, trial counts from the trial registries.

The trials here

What the 356 trials at this site are about, from their registry records.

Conditions: Multiple myeloma24 trials
Lung cancer23 trials
Alzheimer disease18 trials
Childhood cancers16 trials
Bladder cancer15 trials
Prostate cancer15 trials
HIV14 trials
Heart failure13 trials
Stroke13 trials
Coronary artery disease12 trials
Colorectal cancer11 trials
Head and neck cancer11 trials
and 84 more
Phase: Phase 367 trials
Phase 253 trials
Phase 137 trials
Phase 1/226 trials
Phase 412 trials
Phase 2/311 trials
Early phase 12 trials
Status: Recruiting115 trials
Active, not recruiting98 trials
Completed90 trials
Not yet recruiting18 trials
Terminated17 trials
Enrolling by invitation11 trials
Withdrawn4 trials
Suspended3 trials
Lead sponsor: Emory University24 trials
Janssen Research & Development, LLC16 trials
Amgen8 trials
Boehringer Ingelheim8 trials
Novartis Pharmaceuticals8 trials
and 195 more

Running trials

Not yet recruiting
Kidney RISE: Randomized Integrated Supportive CarE Trial
NCT07741357· NYU Langone Health· Source
Contact: Dio Kavalieratos, MD (principal investigator)
Not yet recruiting
Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Atlanta
NCT07535346· Emory University· Source
Contact: Samantha Hill, MD, MPH
Not yet recruiting
Topical Curcumin for HPV Related Cervical Disease
NCT04266275· Phase 2· Lisa Flowers· Source
Contact: Lisa Flowers, MD
Not yet recruiting
Electrophysiologic Mechanisms of Ketamine Antidepressant Response
NCT07768618· Phase 2· Emory University· Source
Contact: Carl Hacker, MD, PhD
Recruiting
Thrive With Type 1 Diabetes 2026
NCT07522866· Emory University· Source
Contact: Stephanie Griggs, PhD, RN, FAAN
Not yet recruiting
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
NCT07778602· Early phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source
Contact: Byram H Ozer, MD, PhD
Recruiting
Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)
NCT07665372· Johns Hopkins University· Source
Contact: William Kitchens, MD, PhD
Recruiting
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
NCT07459634· Phase 2· Jazz Pharmaceuticals· Source
Contact: Clinical Trial Disclosure & Transparency
Not yet recruiting
Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease
NCT07675408· Fortis Medical Devices Limited· Source
Contact: Lucas McKay, PhD MSCR
Enrolling by invitation
Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort
NCT07858214· Head Diagnostics· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Contact: Anthony Hunter (principal investigator)
Not yet recruiting
Handgrip Exercise Training and CKD
NCT07094906· Emory University· Source
Contact: Jeanie Park, MD
Not yet recruiting
H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)
NCT07484139· Phase 2· UNC Lineberger Comprehensive Cancer Center· Source
Contact: Nikki C Schmitt
Recruiting
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
NCT07569926· Phase 4· Blue Earth Diagnostics· Source
Contact: Ismaheel Lawal, MD
Recruiting
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
NCT07544654· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NCT07324031· AtaCor Medical, Inc.· Source
Contact: Mikhael El Chami, MD
Not yet recruiting
Early Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program
NCT07623759· Emory University· Source
Contact: Allison J Schwartz, PhD
Not yet recruiting
An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function
NCT07613398· Matthias Stuber· Source
Contact: John Oshinski, PhD
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
NCT07422480· Phase 3· Takeda· Source
Contact: Nikolaos Papadantonakis (principal investigator)
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702· Insulet Corporation· Source
Contact: Sabeena Usman
Active, not recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Horizon Two: HR NDMM (MMRC-100)
NCT07053436· Phase 2· Multiple Myeloma Research Consortium· Source
Contact: Bryan Burton
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study
NCT07676565· Indiana University· Source
Contact: sabeena usman
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Gideon T Dosunmu, Site 0377
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
NCT07379827· Bristol-Myers Squibb· Source
Contact: Robert Cotes, Site 0025
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003· Phase 3· Prilenia· Source
Contact: Wanda Sanchez
Recruiting
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07219212· Phase 1· Johnson & Johnson Enterprise Innovation Inc.· Source
Recruiting
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
NCT07187973· Phase 1· Disc Medicine, Inc· Source
Contact: Sonjile James
Recruiting
Tofersen in Non-SOD1 ALS
NCT07294144· Phase 2· Washington University School of Medicine· Source
Contact: Karon Simmons
Recruiting
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
NCT07288359· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Kelsey Gates
Active, not recruiting
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
NCT07107945· Phase 3· Boehringer Ingelheim· Source
Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
NCT07206225· Phase 1· Pfizer· Source
Recruiting
BoxX-NoAF Clinical Trial
NCT06989775· AtriCure, Inc.· Source
Contact: Jayne Thompson
Recruiting
Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
NCT07143669· Blueprint Medicines Corporation· Source
Contact: Blueprint Medicines
Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
NCT07206056· Phase 1/2· Novartis Pharmaceuticals· Source
Contact: Wilena Session
Recruiting
ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
NCT06800963· Phase 1/2· ImmunityBio, Inc.· Source
Contact: Fana Cisse
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
Study of COYA 302 for the Treatment of ALS
NCT07161999· Phase 2/3· Coya Therapeutics· Source
Recruiting
A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)
NCT07037758· Phase 1· Amgen· Source
Recruiting
JAK Signaling in Depression
NCT07003997· Phase 2· Emory University· Source
Contact: Jennifer Felger, PhD
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318· Phase 3· Takeda· Source
Contact: Ana Antun (principal investigator)
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· Phase 1/2· BioNTech SE· Source
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113· Phase 1· Amgen· Source
Recruiting
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
NCT07002034· Phase 2· Reunion Neuroscience Inc· Source
Contact: Joyelle Van Eron
Not yet recruiting
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
NCT06989567· Phase 3· Asklepion Pharmaceuticals, LLC· Source
Contact: Claudia Morris, MD

Showing 50 of 242.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Prostate cancer10 recruiting
Lung cancer9 recruiting
Bladder cancer7 recruiting
Parkinson disease7 recruiting
Colorectal cancer6 recruiting
Head and neck cancer6 recruiting
Multiple myeloma6 recruiting
Alzheimer disease5 recruiting
Childhood cancers5 recruiting
Chronic kidney disease5 recruiting
Coronary artery disease5 recruiting
Stroke5 recruiting
Type 1 diabetes5 recruiting
Acute myeloid leukaemia4 recruiting
ALS (motor neurone disease)4 recruiting
Atrial fibrillation4 recruiting
Crohn's disease4 recruiting
Depression4 recruiting
Gastric and oesophageal cancer4 recruiting
Myelodysplastic syndromes4 recruiting
Myeloproliferative neoplasms4 recruiting
Pancreatic cancer4 recruiting
Acute lymphoblastic leukaemia3 recruiting
Cervical cancer3 recruiting
Glioblastoma3 recruiting
HIV3 recruiting
Idiopathic pulmonary fibrosis3 recruiting
Melanoma3 recruiting
Ovarian cancer3 recruiting
Sickle cell disease3 recruiting
Triple-negative breast cancer3 recruiting
Aortic aneurysm2 recruiting
Autism2 recruiting
Cystic fibrosis2 recruiting
Endometrial cancer2 recruiting
Frontotemporal dementia2 recruiting
Heart failure2 recruiting
High blood pressure2 recruiting
Immune thrombocytopenia (ITP)2 recruiting
Lewy body dementia2 recruiting
Lupus (SLE)2 recruiting
Metastatic breast cancer2 recruiting
Multiple sclerosis2 recruiting
Multiple system atrophy2 recruiting
Osteoporosis2 recruiting
Type 2 diabetes2 recruiting
ANCA-associated vasculitis1 recruiting
Aortic stenosis1 recruiting
Brain aneurysm1 recruiting
Chronic myeloid leukaemia1 recruiting
CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
Congenital heart disease1 recruiting
Dystonia1 recruiting
Epilepsy1 recruiting
Essential tremor1 recruiting
Long COVID and ME/CFS1 recruiting
Macular degeneration1 recruiting
Neuroendocrine tumours1 recruiting
Osteoarthritis1 recruiting
Pompe disease1 recruiting
Postural tachycardia syndrome (POTS)1 recruiting
Psoriasis1 recruiting
Psoriatic arthritis1 recruiting
Pulmonary arterial hypertension1 recruiting
Schizophrenia1 recruiting
Ulcerative colitis1 recruiting
Ventricular tachycardia1 recruiting

Closed trials

Completed
Simplified Onboarding in Adults With Type 2 Diabetes
NCT07070830· Insulet Corporation· Source
Terminated
VIZ ACCESS HCM - Multi-Site Registry
NCT07103057· Viz.ai, Inc.· Source
Recruiting
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Completed
Innovative Automated Insulin Delivery System for Type 2 Diabetes
NCT06853990· Deka Research and Development· Source
Terminated
Study of the Oral Treatment MTR-601 in Cervical Dystonia
NCT06830642· Phase 2· Motric Bio· Source
Completed
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122· Boehringer Ingelheim· Source
Terminated
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
NCT06042257· Phase 2· Rachel G. Greenberg, MD, MB, MHS· Source
Withdrawn
REVERSE-Long COVID-19 With Baricitinib Study
NCT05858515· Phase 3· Vanderbilt University Medical Center· Source
Completed
RECOVER-SLEEP: Platform Protocol
NCT06404086· Phase 2· Duke University· Source
Completed
Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes
NCT06127251· Emory University· Source
Completed
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526· Phase 3· GB002, Inc.· Source
Completed
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528· Phase 3· Boehringer Ingelheim· Source
Completed
Web-based Physical Activity Intervention to Promote Physical Activity
NCT05803304· Emory University· Source
Completed
HEAL-LAA Clinical Trial
NCT05809596· Boston Scientific Corporation· Source
Terminated
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
NCT06026332· Ferring Pharmaceuticals· Source
Completed
Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening
NCT06561217· University of Pennsylvania· Source
Recruiting
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
NCT05836259· Phase 1/2· Tenaya Therapeutics· Source
Contact: Matt Pollman, M.D.
Terminated
Achieving Portal Access With Scorpion Post-Approval Study (APASS)
NCT05765253· Argon Medical Devices· Source
Completed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501· Phase 2· Hoffmann-La Roche· Source
Terminated
Effectiveness Trial of Mobile ESI for Toddlers With Autism Identified by Early Screening in Primary Care
NCT05456139· Florida State University· Source
Completed
NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial
NCT05666713· National Heart, Lung, and Blood Institute (NHLBI)· Source
Completed
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
NCT05624268· Phase 3· COMPASS Pathways· Source
Completed
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
NCT05653271· Phase 1· Acepodia Biotech, Inc.· Source
Terminated
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
NCT05068726· GE Healthcare· Source
Completed
Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes
NCT05644730· Ideal Medical Technologies· Source
Completed
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT05467176· Sumitomo Pharma America, Inc.· Source
Completed
Pharmacy-based Pre-exposure Prophylaxis
NCT04393935· Emory University· Source
Completed
Efficacy in iNPH Shunting (PENS) Trial
NCT05081128· Johns Hopkins University· Source
Completed
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
NCT05347485· Phase 2· Janssen Scientific Affairs, LLC· Source
Completed
Time in Glucose Hospital Target
NCT05135676· Jaeb Center for Health Research· Source
Withdrawn
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
NCT05204160· Phase 2· Emory University· Source
Terminated
Prevention of NAFLD in Hispanic Children
NCT05292352· Emory University· Source
Completed
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
NCT05241834· Phase 1· Eli Lilly and Company· Source
Completed
Telemedicine in Early Childhood Constraint Therapy in Cerebral Palsy
NCT04997109· Emory University· Source
Completed
Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)
NCT05276349· St. Joseph's Hospital and Medical Center, Phoenix· Source
Completed
Achieving Portal Access With Scorpion Post-Approval Study 2
NCT06856655· Argon Medical Devices· Source
Completed
Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain
NCT04906447· Phase 2· University of Illinois Chicago· Source
Terminated
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
NCT03919162· Phase 2· Vivoryon Therapeutics N.V.· Source
Completed
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
NCT05172024· NYU Langone Health· Source
Terminated
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT05119335· Phase 1/2· NiKang Therapeutics, Inc.· Source
Terminated
Study of INCA 0186 in Subjects With Advanced Solid Tumors
NCT04989387· Phase 1· Incyte Corporation· Source
Completed
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT05024045· Phase 1· Eli Lilly and Company· Source
Completed
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
NCT05006352· Phase 1· Denali Therapeutics Inc.· Source
Completed
Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
NCT04948866· University of North Carolina, Chapel Hill· Source
Completed
Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention
NCT04923880· Massachusetts General Hospital· Source
Completed
Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome
NCT04873934· Phase 3· Novartis Pharmaceuticals· Source
Completed
MINDS Imaging Ancillary Study
NCT05270356· University of Pittsburgh· Source
Terminated
To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)
NCT04551053· Phase 3· Incyte Corporation· Source
Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066· Phase 3· Incyte Corporation· Source
Completed
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
NCT04880434· Phase 2· Kite, A Gilead Company· Source

Showing 50 of 111.

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error